CD274 and non-small cell lung carcinoma: Various large randomized clinical trials have shown that immune checkpoint inhibitors (ICIs) could significantly improve the survival of NSCLC patients when compared with conventional chemotherapy (13, 14), several anti-PD1/PD-L1 antibodies have been used for antitumor therapy in clinical (15).